A cohort study to examine the effect of 10-valent pneumococcal-Haemophilus influenzae protein D conjugate vaccine (PHiD-CV, Synflorix, Registered Trademark) on the frequency of non-typeable Haemophilus influenzae (NTHi) infection in the upper and lower airways of children

This study looks at whether a vaccine called PHiD-CV (Synflorix) protects children from a type of bacteria called non-typeable Haemophilus influenzae (NTHi), which can cause lung infections. Researchers want to know how often NTHi still shows up in the airways of children who received this vaccine. You may be eligible if: - Your child is between 1 and 19 years old - Your child is already scheduled for a bronchoscopy (a procedure to look inside the airways) - Your child has received at least one dose of the PHiD-CV vaccine more than a month before the bronchoscopy - OR your child has never received any PHiD-CV vaccine You may NOT be eligible if: - Your child was already enrolled in this study before - Your child has cystic fibrosis - Your child has an immune system disorder - Your child has interstitial lung disease Talk to your doctor about whether this trial might be right for you.